Pyrimethamine
Mostrando 1-12 de 193 artigos, teses e dissertações.
-
1. Lack of quadruple and quintuple mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax isolates from Brazilian endemic areas
BACKGROUND AND OBJECTIVE Brazil is responsible for a large number of Plasmodium vivax cases in America. Given the emergence of P. vivax parasites resistant to chloroquine and the effectiveness of antifolates in vivax malaria treatment together with a correlation between mutations in P. vivax dhfr and dhps genes and SP treatment failure, the point mutations
Mem. Inst. Oswaldo Cruz. Publicado em: 04/02/2019
-
2. MOLECULAR SURVEILLANCE OF Plasmodium vivax AND Plasmodium falciparum DHFR MUTATIONS IN ISOLATES FROM SOUTHERN IRAN
In Iran, both Plasmodium vivax and P. falciparum malaria have been detected, but P. vivax is the predominant species. Point mutations in dihydrofolate reductase (dhfr) gene in both Plasmodia are the major mechanisms of pyrimethamine resistance. From April 2007 to June 2009, a total of 134 blood samples in two endemic areas of southern Iran were collected fro
Rev. Inst. Med. trop. S. Paulo. Publicado em: 22/03/2016
-
3. Congenital toxoplasmosis in a reference center of Paraná, Southern Brazil
This study describes the characteristics of 31 children with congenital toxoplasmosis children admitted to the University Hospital of Londrina, Southern Brazil, from 2000 to 2010. In total, 23 (85.2%) of the mothers received prenatal care but only four (13.0%) were treated for toxoplasmosis. Birth weight was <2500 g in 37.9% of the infants. During the first
Braz J Infect Dis. Publicado em: 2014-08
-
4. Sequence analysis of genes associated with resistance to chloroquine and sulphadoxine pyrimethamine in P. falciparum and P. vivax isolates from the Bannu district of Pakistan
Plasmodium vivax and Plasmodium falciparum are becoming resistant to drugs including antifolates, sulphonamides and chloroquine. This study was focused at sequence analysis of resistant genes of these parasites against sulphadoxine-pyrimethamine and chloroquine, from Bannu, Pakistan. Known mutations were detected at codons 57, 58 and 117 of pvdhfr gene of P.
Braz J Infect Dis. Publicado em: 2013-10
-
5. The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine
The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei. A marked potentiation was observed when MB was administered at a non-curative dose of 15 mg/kg/day in combination with PYR (0.19 mg/k
Mem. Inst. Oswaldo Cruz. Publicado em: 2012-09
-
6. Multicomponent complex formation between pyrimethamine, cyclodextrins and water-soluble polymers
The combined effect of hydroxypropyl-β-cyclodextrin (HPβCD) and polyvinylpyrrolidone (PVP) or sodium carboxymethylcellulose (CMC) on the solubility of pyrimethamine (PYR) was studied. Equimolar PYR-HPβCD solid systems, in the presence or the absence of 0.25% (w/v) PVP or 0.10% (w/v) CMC were prepared by coevaporation or freeze-drying, and characterized by
Brazilian Archives of Biology and Technology. Publicado em: 2011-10
-
7. Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control
In Brazil, malaria still remains a clinically important febrile syndrome for local populations and travelers, occurring mostly in the Amazon Basin. This review aims to report the main efforts employed to control this disease since the 1940s and the emergence of Plasmodium falciparum and Plasmodium vivax chemoresistance to chloroquine and sulphadoxine-pyrimet
Memórias do Instituto Oswaldo Cruz. Publicado em: 2011-08
-
8. Change in mutation patterns of Plasmodium vivax dihydrofolate reductase (Pvdhfr) and dihydropteroate synthase (Pvdhps) in P. vivax isolates from malaria endemic areas of Thailand
Malaria is the most important public health problem in several countries. In Thailand, co-infections of Plasmodium vivax and Plasmodium falciparum are common. We examined the prevalence and patterns of mutations in P. vivax dihydrofolate reductase (Pvdhfr) and P. vivax dihydropteroate synthase (Pvdhps) in 103 blood samples collected from patients with P. viv
Memórias do Instituto Oswaldo Cruz. Publicado em: 2011-08
-
9. Disseminated toxoplasmosis in an immunocompetent patient from Peruvian Amazon
We report a case of severe toxoplasmosis in an immunocompetent patient, characterized by pneumonia, retinochoroiditis, hepatitis and myositis. Diagnosis was confirmed by serology, T. gondii in thick blood smear and presence of bradyzoites in muscle biopsy. Treatment with pyrimethamine plus sulfadoxine was successful but visual acuity and hip extension were p
Revista do Instituto de Medicina Tropical de São Paulo. Publicado em: 2010-04
-
10. Estudos calorimétricos da adsorção e liberação da pirimetamina e sulfadiazina em matriz de quitosana quimicamente modificada
Este trabalho teve como objetivo o estudo da interação dos fármacos pirimetamina (PIR) e sulfadiazina (SDZ) com o biopolímero quitosana modificado quimicamente com gluteraldeído e tendo cobre imobilizado (Quit-Cu), bem como o estudo de liberação desses fármacos em tampão pH 7,0 através da calorimetria isotérmica. As matrizes de quitosana modificad
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 21/05/2009
-
11. Characterisation of pvmdr1 and pvdhfr genes associated with chemoresistance in Brazilian Plasmodium vivax isolates
Plasmodium vivax control is now being hampered by drug resistance. Orthologous Plasmodium falciparum genes linked to chloroquine or sulfadoxine-pyrimethamine chemoresistance have been identified in P. vivax parasites, but few studies have been performed. The goal of the present work is to characterise pvmdr1 and pvdhfr genes in parasite isolates from a Brazi
Memórias do Instituto Oswaldo Cruz. Publicado em: 2009-11
-
12. Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis
Clinical trials comparing different drug regimens and strategies for the treatment of congenital toxoplasmosis and its clinical manifestations in the liveborn child in different clinical settings should aim at formally evaluating the net benefit of existing treatments and at developing new therapeutic options. Currently, there is no ideal drug for congenital
Memórias do Instituto Oswaldo Cruz. Publicado em: 2009-03